Onxeo
49 boulevard du Général Martial Valin
Paris
75015
France
Tel: 33-0-1-45-58-76-00
Fax: 33-0-1-45-58-08-81
Website: http://www.onxeo.com/
Email: contact@onxeo.com
About Onxeo
123 articles about Onxeo
-
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
4/7/2022
Onxeo S.A., hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response, announced the appointment of Dr. Shefali Agarwal as President and Chief Executive Officer.
-
Onxeo Continues to Strengthen its Board of Directors
11/23/2021
Onxeo S.A. announced the appointment of Bryan Giraudo as independent member of the Board of Directors, replacing Thomas Hofstaetter after three mandates.
-
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
10/14/2021
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategyat Sanofi, join the Company’s Board as independent members.
-
Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States
6/9/2021
Onxeo S.A . today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA.
-
Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts
5/31/2021
This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of Onxeo’s current and future programs
-
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
9/8/2020
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that its management team will attend the following key investor conferences in the coming months: H.C. Wainwright 22 nd Annual Global Investment Conference September
-
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
9/3/2020
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration in the treatment of TNBC and chemo-resistant lung cancer, alone or in combination with chemotherapy, radiotherapy or other tumor DNA-damaging agents Patent to be granted in the U.S. until 2037
-
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
8/27/2020
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose used today in the ongoing DRIIV-1b and REVOCAN studies of AsiDNA™ in combination with chemotherapy and PARP inhibitors
-
Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties
6/25/2020
Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response, in particular against rare or resistant cancers, announced the confirmation of the preclinical profile of OX401, the second candidate from its platON™ platform.
-
New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020
6/22/2020
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells
-
BioSpace Global Roundup, June 11
6/11/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Onxeo Announces Approval of the REVocan Study by Regulatory Authorities
5/29/2020
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer
-
Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation
5/27/2020
Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response, in particular against rare or resistant cancers, announced the publication of an initiation report by Bryan Garnier & Co, a leading independent European financial services company specialized in research, execution and advisory services.
-
Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi
5/19/2020
Onxeo S.A. announced the presentation of preclinical data supporting the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response inhibitor, to reverse resistance to PARP inhibitors by preventing death-tolerant cells regrowth.
-
Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update
4/17/2020
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today reported its consolidated financial results for the fiscal ending December 31, 2019, and provided a business update.
-
Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer
1/29/2020
The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer
-
Onxeo Publishes Shareholder Newsletter
1/20/2020
Onxeo S.A.,, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response, in particular against rare or resistant cancers, announces the publication of its shareholder letter.
-
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
11/13/2019
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity
-
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
11/4/2019
Onxeo S.A. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office, granting the Company a new patent covering the combination of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, with any PARP inhibitor for cancer treatment, in the United States.
-
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
1/3/2019
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the identification of predictive biomarkers for AsiDNA™, its first-in-class non-targeted DNA Damage Response (DDR) inhibitor, which enables personalized medicine approaches.